Target Validation

News Target Validation

• GVK Biosciences announces multi-year drug discovery collaboration with the Moulder Center for Drug Discovery Research, Temple University

  GVK Biosciences announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.  As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification more

• Cenix signs RNAi research agreement with SYGNIS

  Cenix BioScience GmbH announced that it has signed a research agreement with Heidelberg-based SYGNIS Bioscience GmbH & Co. KG. Under the research agreement’s first assignment to advance the SYGNIS KIBRA project, Cenix will apply its long-standing expertise in combining high content screening with ge more

• Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington’s Disease

  Evotec AG announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington’s disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, wi more

White papers Target Validation

• Outstanding Microarray Experimental Results Using FuGENE® HD Transfection Reagent
  

  Transfection is a method for delivering nucleic acids, either DNA or RNA, into animal cells in vitro. In applications such as protein production, the main purpose is to produce protein; consequently any effects on endogenous gene expression are generally irrelevant, unless the changes relate directly to loss of the cell's ability to produce protein, i.e., cell death. In contrast, in applications where the biochemical pathways are of interest, changes within the cell can alter the interpretation of the data. Unintended up- or down-regulation of genes within transfected cells is termed an off-target effect. This may be caused by the reagent itself, the vector, or the process of transfection. Such effects, if not carefully evaluated, may lead to misinterpretation of the transfection results and to misleading conclusions. Critically important in transfection experiments is the selection of the appropriate control. more

Publications Target Validation

• Use of a Single Hybrid Imaging Agent for Integration of Target Validation with In Vivo and Ex Vivo Imaging of Mouse Tumor Lesions Resembling Human DCIS

  by Tessa Buckle, Joeri Kuil, Nynke S. van den Berg, Anton Bunschoten, Hildo J. Lamb, Hushan Yuan, Lee Josephson, Jos Jonkers, Alexander D. Borowsky, Fijs W. B. van Leeuwen Methods A hybrid CXCR4 targeting peptide (MSAP-Ac-TZ14011) containing a fluorescent dye and a chelate for radioactive labelin more

• 4′-Phosphopantetheinyl Transferase PptT, a New Drug Target Required for Mycobacterium tuberculosis Growth and Persistence In Vivo

  by Cécile Leblanc, Thomas Prudhomme, Guillaume Tabouret, Aurélie Ray, Sophie Burbaud, Stéphanie Cabantous, Lionel Mourey, Christophe Guilhot, Christian Chalut The cell envelope of Mycobacterium tuberculosis, the causative agent of tuberculosis in humans, contains lipids with unusual struc more

• Putative Impact of RNA Editing on Drug Discovery

  Virtually all organisms use RNA editing as a powerful post‐transcriptional mechanism to recode genomic information and to increase functional protein diversity. The enzymatic editing of pre‐mRNA by ADARs and CDARs is known to change the functional properties of neuronal receptors and ion channels more

Market studies Target Validation

• Deltagen, Inc. (DGEN) - Financial and Strategic SWOT Analysis Review

  Deltagen, Inc. (Deltagen) is a pharmaceutical company, that is engaged in providing drug discovery tools and services to the biopharmaceutical industry and to the academic research institutes. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including acce more

• NascaCell Technologies AG (N7C) - Financial and Strategic SWOT Analysis Review

  Nascacell Technologies AG (Nascacell) is a publicly held company specialized in the development of products and drug development candidates based on the proprietary Microbody technology. The company offers a range of new generation biomolecules to the healthcare industry. Its customers are spread ac more

• NeoGenomics, Inc. (NGNM) - Financial and Strategic SWOT Analysis Review

  NeoGenomics, Inc., (NeoGenomics) is a publicly held pharmaceutical company. It is principally engaged in providing cancer-related diagnostic services through its network of laboratories. The company focuses on the genetic and molecular testing segment of the medical laboratory market. The service po more

Websites Target Validation